BMS, Van­tAI team up; CRISPR Ther­a­peu­tics to raise $280M; Ono Phar­ma's deal with Shat­tuck Labs

Plus, news about Areteia Ther­a­peu­tics, Su­do Bio­sciences, Cidara Ther­a­peu­tics, Xspray Phar­ma and Sana Biotech­nol­o­gy:

Bris­tol My­ers Squibb inks deal with Van­tAI: The pair plan to use Van­tAI’s gen­er­a­tive AI plat­form to de­sign mol­e­c­u­lar glues as small mol­e­cule drugs, with the op­tion to ex­pand to more pro­grams in the fu­ture. Van­tAI could re­ceive up to $674 mil­lion in mile­stones plus tiered roy­al­ties. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER